Literature DB >> 3776550

In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man.

C Bäärnhielm, H Dahlbäck, I Skånberg.   

Abstract

The elimination of felodipine in liver microsomes from dog and man were characterized by Km and Vmax. The results were compared with previous data reported for rat. In all species studied, felodipine was primarily metabolized to its corresponding pyridine analogue. The elimination rate order was rat greater than dog greater than man. The same species difference was observed in vivo for the oral plasma clearance which was; rat 26 1/hr/kg, dog 7.5 1/hr/kg and man 4.3 1/hr/kg. The intrinsic hepatic clearance of felodipine was predicted in vitro from Vmax over Km. The in vitro values were not significantly different from those observed in vivo. Felodipine is a high-clearance drug and the in vivo extraction ratios were about the same in all species: rat 0.80, dog 0.83 and man 0.84. The extraction ratios predicted from the in vitro studies, rat 0.91, dog 0.70 and man 0.80, agreed well with those observed in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3776550     DOI: 10.1111/j.1600-0773.1986.tb00142.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  20 in total

Review 1.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver.

Authors:  Z E Wilson; A Rostami-Hodjegan; J L Burn; A Tooley; J Boyle; S W Ellis; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 3.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

4.  Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance.

Authors:  Nancy Hakooz; Kiyomi Ito; Helen Rawden; Helen Gill; Lynn Lemmers; Alan R Boobis; Robert J Edwards; David J Carlile; Brian G Lake; J Brian Houston
Journal:  Pharm Res       Date:  2006-02-28       Impact factor: 4.200

5.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

6.  Nonspecific binding of drugs to human liver microsomes.

Authors:  J A McLure; J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

7.  Evaluation of first pass effect and biliary excretion of diperdipine in the dog.

Authors:  P O Greiner; S Weber; J Angignard; B Berbey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

8.  Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine.

Authors:  Aki T Heikkinen; Arno Friedlein; Mariette Matondo; Oliver J D Hatley; Aleksanteri Petsalo; Risto Juvonen; Aleksandra Galetin; Amin Rostami-Hodjegan; Ruedi Aebersold; Jens Lamerz; Tom Dunkley; Paul Cutler; Neil Parrott
Journal:  Pharm Res       Date:  2014-07-18       Impact factor: 4.200

9.  Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid.

Authors:  Guillaume A Schoch; Jason K Yano; Stefaan Sansen; Patrick M Dansette; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2008-04-15       Impact factor: 5.157

10.  Metabolism of [14C] felodipine, a new vasodilating drug, in healthy volunteers.

Authors:  K J Hoffmann; L Andersson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.